White House strikes new deals to lower prices on obesity drugs for some

By Sydney Lupkin

Published November 7, 2025 at 2:56 AM MST

Facebook
Flipboard
LinkedIn
Email

The Trump administration struck deals with pharmaceutical companies Novo Nordisk and Eli Lilly to lower prices and copays for type 2 diabetes and obesity drugs --- but not everyone will qualify.

Facebook
Flipboard
LinkedIn
Email

Sydney Lupkin

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

See stories by Sydney Lupkin

Make a monthly donation

Become a sustaining member for as low as $5/month

Make a one-time donation

Make an annual or one-time donation to support MTPR

Pay pledge or update info

Pay an existing pledge or update your payment information